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the prototype.  It was clearly a significant 
improvement over what is available and 
generated a buzz amongst clinicians and 
early stage investors.
Regarding providing medical services side 
for epilepsy, EpiNightNurse an Internet-
based system for nightly video and audio 
monitoring of patients with epilepsy 
was presented by Tamara and Joachim 
Coche, parents of a son with epilepsy 
from Scandinavia.  The system consists 
of a real time video recording of a patient 
at night being viewed by specially trained 
epilepsy nurses in the Philippines who 
can then communicate back with care-
givers.  Essentially the Coche’s created 
a business of a new system of care for 
epilepsy patients and monitoring and 
demonstrated how it works.  Using time 
differences and technology they devel-
oped a method for an adjunctive way to 
monitor patients and it will be exciting to 
see how it grows and develops.
It is great for patients and physicians with 
epilepsy who are in need of new therapies 
that this annual conference occurs.  We 
encourage you to attend and be involved 
if you can as the evolution and changes 
in the field are exciting to see first hand.
Each year the Epilepsy Therapy Project in conjunction with the Epilepsy Foun-
dation puts on a conference for new development in diagnostics, device and 
medication therapies emerging in the field of epilepsy. We summarize below a 
few of the presentations that we thought would be of interest to the JHN reader-
ship. For a full listing of the presentations please see http://www.epilepsy.com/
accelerating-new-therapies/2016-epilepsy-pipeline-conference.  
In the new mechanism of action therapies there were three new products that were 
presented. Scotts Edwards updated the conference on progress of the compound 
SF0034 which a potent and selective KCNQ2/3 activator designed to suppress neuronal 
hyperexcitability in patients with partial-onset epilepsy. SF0034 was found to have 
significantly greater potency and selectivity in preclinical models of epilepsy compared 
with the known product ritagabine. Tansna President Mark Robbins, presented progress 
fir a new novel non-sedating agent derived from propofol which in early work had a 
favorable efficacy and side effect profile.  Michael Ragowski presented on a new Inhaled 
treatment for refractory epilepsy, which is a prodrug of propofol, as a potential rescue 
for patients having seizures and want to try and avoid the oncoming seizure.  Lastly 
and for a similar target, Jackie French presented data on Phase 2a for a status epileptic 
rescue medication that being developed by Alexza Pharmaceuticals for patients who 
have repetitive seizures and want to stop after the first seizure.  
On the diagnostic side, Rosalind Picard from MIT an affective computing expert, 
presented Empatica’s increasing experience with epilepsy watch data primarily for 
patients generalized tonic clinic seizures. In the newcomer competition, several exciting 
new companies presented, Aswin Gunasekar the CEO of Zeto presented his companies 
new EEG device designed to make ambulatory EEG quicker, cheaper, more accurate, 
with less need for an EEG technician and potentially simplifying EEG review consulta-
tion by an off site Neurologist.  The presentation consisted of having individuals try 
sEEG and Epilepsy 
       Surgery Symposium
October 21 and 22 | Philadelphia, PA
Join a discussion for the latest trends and controversies in 
sEEG and epilepsysurgery. Topics include laser ablation, 
vagal nerve stimulation, responsive neurostimulation and 
an in-depth analysis of sEEG strategies. This is an accredited 
CME course designed for epilepsy neurosurgeons and 
epileptologists.
To register: WillsEye.org/continuing-medical-education
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